Multiple sclerosis management for low-income minorities

被引:38
作者
Shabas, D [1 ]
Heffner, M [1 ]
机构
[1] Independence Care Syst, New York, NY 10010 USA
关键词
DEXA scans; immunomodulatory drugs; multiple sclerosis; osteoporosis;
D O I
10.1191/1352458505ms1215oa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Low-income minorities with complex chronic diseases and physical disabilities have difficulty accessing appropriate healthcare often resulting in suboptimal care. A survey was performed to determine the impact of cultural and socioeconomic factors on the quality of care for low-income minorities with multiple sclerosis (MS) enrolled in Independence Care System (ICS), a Medicaid long-term managed care plan. All 92 ICS members with a diagnosis of MS were surveyed on three aspects of their care: specialty contact, immunomodulating drug therapy and osteoporosis prevention. Of those surveyed, 32% were never seen by an MS specialist. One third were not taking immunomodulatory medications, primarily due to noncompliance caused by a lack of understanding about these drugs. The prevention of osteoporosis and potential fracture in this high-risk population was largely neglected by providers despite the fact that the majority of those surveyed also reported balance difficulties and a history of falling. The survey revealed several deficiencies in the care of low-income minorities with MS. A major issue was the lack of adequate education, particularly about the immunomodulating drugs. Education about the importance of osteoporosis prevention, falls mitigation programmes and rehabilitation evaluations are critical interventions to decrease the risk of fracture.
引用
收藏
页码:635 / 640
页数:6
相关论文
共 24 条
[1]   Nursing home residents with multiple sclerosis: comparisons of African American residents to white residents at admission [J].
Buchanan, RJ ;
Martin, RA ;
Zuniga, M ;
Wang, SJ ;
Kim, M .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (06) :660-667
[2]  
Burks J, 1998, J Spinal Cord Med, V21, P113
[3]   Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis [J].
Cree, BAC ;
Khan, O ;
Bourdette, D ;
Goodin, DS ;
Cohen, JA ;
Marrie, RA ;
Glidden, D ;
Weinstock-Guttman, B ;
Reich, D ;
Patterson, N ;
Haines, JL ;
Pericak-Vance, M ;
DeLoa, C ;
Oksenberg, JR ;
Hauser, SL .
NEUROLOGY, 2004, 63 (11) :2039-2045
[4]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[5]   Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [J].
Goodin, DS ;
Frohman, EM ;
Garmany, GP ;
Halper, J ;
Likosky, WH ;
Lublin, FD ;
Silberberg, DH ;
Stuart, WH ;
van den Noort, S .
NEUROLOGY, 2002, 58 (02) :169-178
[6]  
HERNDON RM, 2000, INT J MS CARE, V2, P1
[7]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[8]   A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium [J].
Jacobs, LD ;
Wende, KE ;
Brownscheidle, CM ;
Apatoff, B ;
Coyle, PK ;
Goodman, A ;
Gottesman, MH ;
Granger, CV ;
Greenberg, SJ ;
Herbert, J ;
Krupp, L ;
Lava, NS ;
Mihai, C ;
Miller, AE ;
Perel, A ;
Smith, CR ;
Snyder, DH .
MULTIPLE SCLEROSIS JOURNAL, 1999, 5 (05) :369-376
[9]   Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability [J].
Johnson, KP ;
Brooks, BR ;
Cohen, JA ;
Ford, CC ;
Goldstein, J ;
Lisak, RP ;
Myers, LW ;
Panitch, HS ;
Rose, JW ;
Schiffer, RB ;
Vollmer, T ;
Weiner, LP ;
Wolinsky, JS .
NEUROLOGY, 1998, 50 (03) :701-708
[10]   Multiple sclerosis - Severity and progression rate in African Americans compared with whites [J].
Kaufman, MD ;
Johnson, SK ;
Moyer, D ;
Bivens, J ;
Norton, HJ .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2003, 82 (08) :582-590